UK: Cannabis company enjoys major growth
I had to smile at this article for 4 key reasons:
Seriously, though, this article is proof that plant-based medicine can be developed and marketed. Of course, it's great news for GW Pharma but it should also inspire others to follow in their footsteps. And don't forget that patients are also benefitting.
Currently, Sativex is being presribed to those suffering from multiple sclerosis. There are plans already in place, however, for this cannabis medicine to be further developed for the treatment of cancer pain, epilepsy, rheumatoid arthritis and schizophrenia.
Author: Greer Deal, Director of Global Regulatory Services (GRS)